New shigella vaccine shows promise for infants in phase 2 trial
NCT ID NCT06523231
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 30 times
Summary
This study tested a new vaccine called Shigella4V2 to protect infants against shigellosis, a severe diarrheal disease. Researchers gave the vaccine to 110 healthy 9-month-old babies to check its safety and how well it triggers the immune system. The goal was to find the best dose for future use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHIGELLOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
KEMRI - Center for Global Health Research
Kisumu, 578,40100, Kenya
Conditions
Explore the condition pages connected to this study.